References
- Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117(2):244–279.
- European Medicines Agency. Humira Summary of Product Characteristics 2021 [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf [ cited 2022 May 06].
- US Food and Drug Administration. Humira Prescribing Information 2021 [Internet]. Available from: https://www.rxabbvie.com/pdf/humira.pdf [ cited 2022 May 06].
- Coghlan J, He H, Schwendeman AS. Overview of humira biosimilars: current European landscape and future implications. J Pharm Sci. 2021;110(4):1572–1582.
- US Food and Drug Administration. Biosimilar product information. [Internet]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. [ cited 2022 May 06].
- U.S Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for Industry. [Internet]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-productwww.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product [ cited 2022 May 06].
- European Medicines Agency. Biosimilars in the EU [Internet]. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf [ cited 2022 May 06].
- Nash P, Vanhoof J, Hall S, et al. Randomized crossover comparison of injection site pain with 40 mg/0.4 or 0.8 ml formulations of adalimumab in patients with rheumatoid arthritis. Rheumatol Ther. 2016;3:257–270.
- Wynne C, Schwabe C, Lemech C, et al. A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST). Expert Opin Investig Drugs. 2022;31(9):965-976.
- Feldman SR, Reznichenko N, Pulka G, et al. Efficacy, safety and immunogenicity of avt02 versus originator adalimumab in subjects with moderate to severe chronic plaque psoriasis: a multicentre, double-blind, randomised, parallel group, active control, phase iii study. BioDrugs. 2021;35(6):735–748.
- US Food and Drug Administration. Bioanalytical method validation guidance for industry [Internet] [ cited 2022 June 01]. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf
- European Medicines Agency. Guideline on bioanalytical method validation [Internet] [ cited 2022 June 01]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf.
- Marini JC, Anderson M, Cai X-Y, et al. Systematic verification of bioanalytical similarity between a biosimilar and a reference biotherapeutic: committee recommendations for the development and validation of a single ligand-binding assay to support pharmacokinetic assessments. AAPS J. 2014;16(6):1149–1158.
- Civoli F, Kasinath A, Cai X-Y, et al. Recommendations for the development and validation of immunogenicity assays in support of biosimilar programs. AAPS J. 2019;22(1):7.
- US Food and Drug Administration. Immunogenicity testing of therapeutic protein products - developing and validating assays for anti-drug antibody detection. guidance for industry [Internet] [ cited 2022 June 1]. Available from: https://www.fda.gov/media/119788/download.
- European Medicines Agency. Guideline on Immunogenicity assessment of therapeutic proteins [Internet] [ cited 2022 June 01]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf.
- US Food and Drug Administration. Guidance for industry Rheumatoid arthritis: developing drug products for treatment -Draft guidance 2013 [Internet] [ cited 2022 May 06]. Available from: https://www.fdanews.com/ext/resources/files/archives/62813-01/06-07-13-RA.pdf.
- Karlsdottir K, Gunnarsdottir AI, Grondal G, et al. A patients’ perspective towards the injection devices for humira and imraldi in a nationwide switching program. Front Med (Lausanne). 2022;9:799494.
- Shin D, Lee Y, Jeong D, et al. Comparative pharmacokinetics of an Adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects. Drug Des Devel Ther. 2018;12:3799–3805.
- Damjanov N, Kirvalidze N, Kurshvilli N, et al. Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringe. Exp Opin Biol. Ther. [In press].
- Taylor P. Update on the diagnosis and management of early rheumatoid arthritis. Clin Med. 2020;20(6):561–564.
- Bush J, Kawakami K, Muniz R. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects. BMC Pharmacol Toxicol. 2019;20(1):87.
- Sabet A, Dickerson DS, Kunina EE, et al. A randomised controlled trial comparing the pharmacokinetics and tolerability of the proposed adalimumab biosimilar msb11022 delivered via autoinjector and pre-filled syringe in healthy subjects. Rheumatol Ther. 2022;9(2):693–704.